The Manufacturers Life Insurance Company Has $11.87 Million Stock Position in West Pharmaceutical Services, Inc. $WST

The Manufacturers Life Insurance Company lowered its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 32.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,358 shares of the medical instruments supplier’s stock after selling 23,094 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in West Pharmaceutical Services were worth $11,867,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of WST. Elyxium Wealth LLC acquired a new position in shares of West Pharmaceutical Services in the fourth quarter valued at $25,000. CYBER HORNET ETFs LLC bought a new stake in West Pharmaceutical Services in the 2nd quarter valued at $25,000. Cornerstone Planning Group LLC raised its stake in shares of West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 50 shares in the last quarter. Bayban bought a new position in shares of West Pharmaceutical Services during the 4th quarter worth about $27,000. Finally, Private Trust Co. NA lifted its holdings in shares of West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 61 shares during the period. 93.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on WST. Stephens reissued an “overweight” rating and issued a $360.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Wolfe Research started coverage on West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, July 24th. KeyCorp increased their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Finally, Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $364.42.

West Pharmaceutical Services Trading Up 0.0%

WST stock opened at $341.04 on Monday. The business has a fifty day moving average price of $339.80 and a 200 day moving average price of $289.64. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00. The stock has a market capitalization of $24.00 billion, a price-to-earnings ratio of 43.67, a P/E/G ratio of 2.38 and a beta of 1.15. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same quarter in the previous year, the firm earned $1.84 earnings per share. The business’s revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 8.94 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be issued a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is currently 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.